From I.P to N.P A Call for a New Paradigm. Dr A. Schwartz
|
|
- Avis Clarke
- 8 years ago
- Views:
Transcription
1 From I.P to N.P A Call for a New Paradigm Dr A. Schwartz
2 The Innovative Pharmaceutical business model Big Pharma identifies unmet clinical need Innovator loses Revenue on Older Products, Necessitating development of new products Through R&D new breakthrough therapies are brought to the market Innovator rewarded through IP exclusivity 2 all rights reserved Aharon Schwartz 19/11/2013
3 Tzures in Paradise o The Innovative Pharmaceutical business model faces multiple challenges: Innovation draught Innovation quality & value Shorter effective patent life I.P. uncertainty 3 all rights reserved Aharon Schwartz 19/11/2013
4 Innovation draught o 4 all rights reserved Aharon Schwartz 19/11/2013
5 Innovation draught? Yes In 2012 FDA Approved 39 products. However: only 35 of the 39 were drugs Only 15/35 targeted new MOA. The rest offering, for the most part, minor benefits over already-approved therapeutic options. Only 7/35 offer treatment for conditions where there was no real previous options 5/7 were in indications that are not just orphan but ultratiny. 2/7 ( Belviq & Fulyzaq ) have the potential to treat more than a few thousand patients. 5 all rights reserved Aharon Schwartz 19/11/2013
6 Value for Money? Prescrire ( ) Rating # % Bravo 7 0.2% A real advance % Offers an advantage % Possibly helpful % Nothing new 1, % Not acceptable % Judgment reserved % Total 2, all rights reserved Aharon Schwartz 19/11/2013
7 I.P.- "From here to eternity"? "Filing numerous patent applications for the same medicine [ ] is a common practice. [ ] an important objective of this approach is to delay or block the market entry of generic medicines - לטיפול ביל"דXמולקולה Xתהליךסינתזה 1 של Xתהליךסינתזה 2 של X של Mesylateמלח X שלI פולימורף Xפסוידופולימורף אנהידראט של X שלSuccinateמלח באי ספיקת לבXטיפול ב all rights reserved Aharon Schwartz 19/11/2013
8 I.P Stifles Competition o individual medicines are protected by up to nearly 100 product-specific patent families [ ] this can lead to uncertainty for generic competitors affecting their ability to enter the market. o "Enforcing patent rights in court is legitimate and a fundamental right [ ] however, that litigation can also be an efficient means of creating obstacles for generic companies, in particular for smaller ones. In certain instances originator companies may consider litigation not so much on its merits, but rather as a signal to deter generic entrants. 8 all rights reserved Aharon Schwartz 19/11/2013
9 I.P. Uncertainties o Of ca patent opposition lodged during 2008 to the European Patent Office: Only 28.6% have been rejected 31.6% were partially accepted 39.8% accepted o In the U.S 75% of patent infringement prosecution denied In 45% of the patent infringement cases the patents were found in-valid. 9 all rights reserved Aharon Schwartz 19/11/2013
10 Insufficient exclusivity period? o Drug developments eats over 50% of the 20 years patent life. o Additional (however insufficient) exclusivity periods are granted: Orphan drugs Patent term extensions NME & New Formulations o The need to provide pharmacoeconomic price justification creates additional hurdles. 10 all rights reserved Aharon Schwartz 19/11/2013
11 In summary o The current I.P. system does not provide an adequate basis for the business model of the innovative drug ecosystem: It does not provide enough support for innovation It does not encourage value creation It does not encourage competition It does not provide high level of certainty It does not provide adequate return on the risky investemnts in drug R&D 11 all rights reserved Aharon Schwartz 19/11/2013
12 From I.P. to N.P- A new Paradigm Patent Exclusivity Based on innovation priority Based on marketing approval priority 12 all rights reserved Aharon Schwartz 19/11/2013
13 Patents & Innovation o Patents will be granted according to current practices o Patents will be examined and approved by only a few major authorities. i.e. US, Europe, Japan o Drug development and commercialization exploiting inventions covered by pending or valid patents will be allowed through compulsory licenses to holders of marketing approval for predetermined royalties on net sales 13 all rights reserved Aharon Schwartz 19/11/2013
14 Standard Marketing Exclusivity Periods o Marketing exclusivity will be granted to the first developer achieving marketing authorization in a territory. o Standard Marketing exclusivity periods will be granted: 12 year for drugs providing significant improvement over currently marketed products 10 years for NME, orphan indications etc. 6 years for NME 3 years for new non patented formulation 14 all rights reserved Aharon Schwartz 19/11/2013
15 Advantages along the Value Chain o Academic institutions conducting basic & applied research will benefit as: Simpler and cheaper mechanism providing IP protection No need to conduct inefficient marketing activities Increased chances for commercialization No loss of economic benefits 15 all rights reserved Aharon Schwartz 19/11/2013
16 Advantages along the Value Chain o Drug companies will benefit as: Compulsory license mechanism ensure IP availability Drug companies can focus on their core competences of drug development & marketing Clear, transparent & high certainty mechanism for obtaining marketing exclusivity 16 all rights reserved Aharon Schwartz 19/11/2013
17 Advantages along the Value Chain o National health systems will benefit from: Rational, predicable and clear time limited marketing exclusivity granted according to product added value Competition encouraged Companies will be pushed to race to the market IP will not limit companies from utilizing best technologies 17 all rights reserved Aharon Schwartz 19/11/2013
18 THANK YOU.
Patents in Europe 2013/2014
In association with Unitary patent and Unified Patent Court: the proposed framework Rainer K Kuhnen Patents in Europe 2013/2014 Helping business compete in the global economy Unitary patent and Unified
More informationStrategies for Worldwide Patent Litigation. Moderator: John R. Thomas Panelists: Trevor M. Cook, Jamison E. Lynch, Mark D. Selwyn
Strategies for Worldwide Patent Litigation Moderator: John R. Thomas Panelists: Trevor M. Cook, Jamison E. Lynch, Mark D. Selwyn Global IP Litigation Strategy: Why Is It Important? Trend toward globalization
More informationS P E C I A L I S T A N D M A S T E R S T U D I E S
University Ss, Cyril and Methodius Skopje FACULTY OF PHARMACY S P E C I A L I S T A N D M A S T E R S T U D I E S Healthcare management and pharmacoeconomics Skopje, 2007 STUDY PLAN -Specialist Studies-
More informationYearbook. Building IP value in the 21st century. Beyond the unitary patent: nothing new under the sun?
Beyond the unitary patent: nothing new under the sun? Anna Barlocci and Mathieu de Rooij, ZBM Patents & Trademarks Yearbook 2015 Building IP value in the 21st century 12 13 14 ZBM Patents & Trademarks
More informationAdopt IP Protections to Ensure Regulatory Exclusivity for Orphan Drugs
30-Second Summary Orphan drugs present unique risks the potential return on investment is inherently constrained by small patient populations and attendant reimbursement challenges. Recognizing these challenges,
More informationar gthe international journal of
Pharmaceuticals: a new frontier in investment treaty arbitration 6 September 2013 Ricardo Ugarte, Franz Stirnimann and Dolores Bentolila of Winston & Strawn in Geneva discuss the increasing willingness
More informationGuidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationPATENTS. Pharmaceutical Product Patenting Strategies
PATENTS Pharmaceutical Product Patenting Strategies 1. What is a product patent? A product patent is a patent giving protection to a product as such, e.g. as an apparatus, a device or a chemical compound.
More informationWhy is FTO important?
Antibodies, Patents and Freedom to Operate: The Monoclonal Maze Timothy J. Shea, Jr. Director Tracy Muller Associate Sterne, Kessler, Goldstein & Fox P.L.L.C. 4 th Annual Antibody Therapeutics Conference
More informationPharmaceutical royalties: a new securitisation frontier Malcolm S Dorris Dechert LLP. Dechert LLP 2007
10 Pharmaceutical royalties: a new securitisation frontier Malcolm S Dorris 2007 Securitisation techniques have been increasingly used in less traditional financings involving a wide variety of asset classes.
More informationEC s Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct
FEBRUARY 2009, RELEASE TWO EC s Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct Susan A. Creighton & Seth C. Silber Wilson, Sonsini, Goodrich and Rosati EC s Preliminary
More informationTACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES
TRANSATLANTIC CONSUMER DIALOGUE WASHINGTON MEETING, 10-12 FEBRUARY 2000 TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES The Commission Services
More informationTestimony of. J. Douglas Richards Partner, Cohen Milstein Sellers & Toll, PLLC
Testimony of J. Douglas Richards Partner, Cohen Milstein Sellers & Toll, PLLC Before the Subcommittee on Intellectual Property, Competition and the Internet of the House Committee on the Judiciary Room
More informationCase 8:09-cv-01193-MRP-MLG Document 8 Filed 10/27/2009 Page 1 of 14
Case :0-cv-0-MRP-MLG Document Filed //00 Page of California Street San Francisco, CA -0 0 Gail J. Standish (SBN: gstandish@winston.com Peter E. Perkowski (SBN: pperkowski@winston.com WINSTON & STRAWN LLP
More informationEROSION OF EXCLUSIVE MARKETING RIGHTS- BOON FOR THE PHARMACEUTICAL SECTOR
IPR & TECHNOLOGY BULLETIN EROSION OF EXCLUSIVE MARKETING RIGHTS- BOON FOR THE PHARMACEUTICAL SECTOR Contents Introduction...2 1. What is EMR?...2 2. Provisions of TRIPS...3 2.1 TRIPS and India s compliance...3
More informationRyerson Digital Media Zone Online Resources Patent Essentials
Maya Medeiros Lawyer, Patent Agent, Trademark Agent T: +1 416.216.4823 maya.medeiros@nortonrosefulbright.com http://www.nortonrosefulbright.com/people/99601/maya- medeiros PATENT ESSENTIALS WHAT IS A PATENT?
More informationIP Valuation. WIPO Workshop on Innovation, Intellectual Asset Management and Successful Technology Licensing: Wealth Creation in the Arab Region
IP Valuation WIPO Workshop on Innovation, Intellectual Asset Management and Successful Technology Licensing: Wealth Creation in the Arab Region Muscat, Oman, December 12 and 13, 2011 Topics Intangibles
More informationGLOBAL PATENT LITIGATION
GLOBAL PATENT LITIGATION Author Guide [A] Aim of the Publication Global Patent Litigation is a looseleaf which aims to fulfill the increasing need for quality information on the strategy and practical
More informationGENEVA STANDING COMMITTEE ON THE LAW OF PATENTS. Fourteenth Session Geneva, January 25 to 29, 2010 PROPOSAL FROM BRAZIL *
WIPO SCP/14/7. ORIGINAL: English DATE: January 20, 2010 E WORLD INTELLECTUAL PROPERT Y O RGANI ZATION GENEVA STANDING COMMITTEE ON THE LAW OF PATENTS Fourteenth Session Geneva, January 25 to 29, 2010 PROPOSAL
More informationACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
More informationApplication of Patent Litigation Strategies to Biosimilars: Is there a difference?
Application of Patent Litigation Strategies to Biosimilars: Is there a difference? Kristof Roox, Partner Crowell & Moring Brussels (kroox@crowell.com) November 19, 2009 Berlin, Germany I. Overview of strategies
More informationSecond medical use patents
Second medical use patents The European Swiss perspective AIPPI Helsinki 2013, Pharma Workshop II Andri Hess Part 1 Second medical use claims the protection they confer 2 Second (or further) medical use
More informationPATENT LITIGATION EUROPE. John J. Allen Professor Charles Gielen Benoit Strowel. Silicon Valley, Orange County, Los Angeles February 2006
PATENT LITIGATION EUROPE John J. Allen Professor Charles Gielen Benoit Strowel Silicon Valley, Orange County, Los Angeles February 2006 The problem with European Patent Law 4 Multiple patents 4 Multiple
More informationNJIPLA s 25th Annual Pharmaceutical / Chemical Patent Practice Update First Applicant Generic Exclusivity and Forfeiture Thereof.
NJIPLA s 25th Annual Pharmaceutical / Chemical Patent Practice Update First Applicant Generic Exclusivity and Forfeiture Thereof December 7, 2011 Andrew S. Wasson Frommer Lawrence & HaugLLP Editor, FDALawyersBlog
More informationWIPO TRAINING OF TRAINERS PROGRAM ON EFFECTIVE INTELLECTUAL PROPERTY ASSET MANAGEMENT BY SMALL AND MEDIUM-SIZED ENTERPRISES (SMEs)
WIPO TRAINING OF TRAINERS PROGRAM ON EFFECTIVE INTELLECTUAL PROPERTY ASSET MANAGEMENT BY SMALL AND MEDIUM-SIZED ENTERPRISES (SMEs) IP Law and Administration in the State of Qatar by Malik Al-Kammaz Saba
More informationPATENT LITIGATION IN MEXICO: OVERVIEW AND STRATEGY
PATENT LITIGATION IN MEXICO: OVERVIEW AND STRATEGY SUBSTANTIVE ISSUES IN PATENT LITIGATION IN MEXICO Global E-Commerce Law and Business Report. September, 2003. Patent infringement actions. The Mexican
More informationBreakthrough Therapy Program U.S. Food and Drug Administration (FDA)
Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Presentation before the European Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP) Jarilyn Dupont,
More informationRESEARCH & INNOVATION INTELLECTUAL PROPERTY (IP)
RESEARCH & INNOVATION INTELLECTUAL PROPERTY (IP) What is Intellectual Property (IP)? Intellectual Property (IP) includes different types of invention, design, brand name or original creation There are
More informationRecent Changes in U.S. Patent Law Affecting Cloud Services
Recent Changes in U.S. Patent Law Affecting Cloud Services Robert S. Blasi, Esq. Partner, Intellectual Property Transactions & Strategies November 7, 2012 2012 Goodwin Procter LLP About Goodwin Procter
More informationPharmaceutical royalties: a new securitisation frontier
Pharmaceutical royalties: a new securitisation frontier Dechert LLP This article first appeared in Global Securitisation and Structured Finance 2004, published by Globe White Page Ltd, www.globalsecuritisation.com.
More informationEfficient alternative dispute resolution (ADR) for intellectual property disputes
13.1 Efficient alternative dispute resolution (ADR) for intellectual property disputes More and more rights holders are recognizing the benefits of using private neutral mechanisms that allow parties to
More informationFederal Circuit Clears the Way for Large False Patent Marking Fines. by Corina Tanasa January 27, 2010
Federal Circuit Clears the Way for Large False Patent Marking Fines by Corina Tanasa January 27, 2010 PATENT MARKING By statute, each patented product must be marked to collect maximum patent damages.
More informationA Guide to Intellectual Property Management & Commercialisation
A Guide to Intellectual Property Management & Commercialisation The following is a brief overview Intellectual Property management & commercialisation focussing on patents and copyright, the most common
More informationThe revival of crossborder
The revival of crossborder injunctions The European Court of Justice recently breathed new life into the phenomenon of cross-border injunctions a cost-effective tool originally developed by the Dutch courts
More informationCI encourages you to share this content, however, in doing so, you may not alter its contents.
Copyright 2015 McCormick, Paulding & Huber LLP All Rights Reserved CI encourages you to share this content, however, in doing so, you may not alter its contents. ctinnovations.com 1 Patents: Beyond the
More informationWhy Have Intellectual Property?
Intellectual Property: Protecting Your Ideas James J. Pohl Timothy A. Doyle April 23, 2009 Why Have Intellectual Property? To protect ideas and expressions and to promote investments in these activities
More informationDrug Re-Examination/Data Exclusivity in JAPAN and Neighboring Countries
Japan Pharmaceutical Manufacturers & Association Drug Re-Examination/Data Exclusivity in JAPAN and Neighboring Countries AIPPI Forum & ExCo Workshop Pharma IV September 6, 2013 at Helsinki Yoichi OKUMURA
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More informationPatent Reissue. Frequently Asked Questions
Patent Reissue Frequently Asked Questions Patent Reissue Frequently Asked Questions 1 Table of Contents 1. WHAT IS A REISSUE PATENT APPLICATION?...2 2. WHAT TYPES OF SITUATIONS CALL FOR A REISSUED PATENT?...2
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationTHE JOHN MARSHALL LAW SCHOOL CENTER FOR INTELLECTUAL PROPERTY LAW. 53 rd ANNIVERSARY CONFERENCE ON DEVELOPMENTS IN INTELLECTUAL PROPERTY LAW
THE JOHN MARSHALL LAW SCHOOL CENTER FOR INTELLECTUAL PROPERTY LAW 53 rd ANNIVERSARY CONFERENCE ON DEVELOPMENTS IN INTELLECTUAL PROPERTY LAW Strategies Regarding Patent Exhaustion After Quanta Timothy C.
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationYou Know It Is Coming: Preparing for the Paragraph IV Letter
You Know It Is Coming: Preparing for the Paragraph IV Letter John Farrell, Fish & Richardson Matt Onaitis, Somaxon William Scarff, Allergan Jonathan Singer, Fish & Richardson Table of Contents Regulatory
More informationCurrent Status and Issues on Patent Protection in a Pharmaceutical Field
Current Status and Issues on Patent Protection in a Life Science Field from a Point of Pharmaceutical Industry Yuji WATANABE * Abstract In order to accelerate the rapid pace of innovation in the life science
More informationGLOSSARY OF PATENT TERMINOLOGY
Economic Analysis and Statistics Division Directorate for Science, Technology and Industry GLOSSARY OF PATENT TERMINOLOGY Applicant...2 Applicant country...2 Application for a patent...2 Application date...2
More informationCLIENT MEMORANDUM. I. The Basics. June 18, 2013
CLIENT MEMORANDUM FTC v. Actavis: Supreme Court Rejects Bright Line Tests for Reverse Payment Settlements; Complex Questions Remain in Structuring Pharmaceutical Patent Infringement Settlements June 18,
More informationThe Prize Fund for HIV/AIDS
The Prize Fund for HIV/AIDS A New Paradigm for Supporting Sustainable Innovation and Access to New Drugs for AIDS: De-Linking Markets for Products from Markets for Innovation May 26, 2011 Introduction
More informationU.S. DEPARTMENT OF JUSTICE/FEDERAL TRADE COMMISSION WORKSHOP AND COMMENT PROCEEDING ON PATENT ASSERTION ENTITIES
U.S. DEPARTMENT OF JUSTICE/FEDERAL TRADE COMMISSION WORKSHOP AND COMMENT PROCEEDING ON PATENT ASSERTION ENTITIES COMMENTS OF THE APPLICATION DEVELOPERS ALLIANCE The Application Developers Alliance ( Alliance
More informationBUSINESS ASPECTS OF PATENTS: A PRIMER FOR THE NON-PATENT LAWYER
BUSINESS ASPECTS OF PATENTS: A PRIMER FOR THE NON-PATENT LAWYER John R. Wetherell, Ph.D., J.D. Partner Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 San Diego, CA 92130-4088 858-509-4022
More informationMaine Cernota & Rardin, Registered Patent Attorneys 547 Amherst St., 3 rd Floor, Nashua, NH 03063 603-886-6100 info@mcr-ip.com
Seven Ways to Control the Cost and Quality of Your Patent Docket In order to be a credible competitor in today s marketplace, companies must develop and manage their intellectual property (IP) assets wisely.
More informationSUBSTITUTE SENATE BILL 5059. State of Washington 64th Legislature 2015 Regular Session
S-1.1 SUBSTITUTE SENATE BILL 0 State of Washington th Legislature 01 Regular Session By Senate Law & Justice (originally sponsored by Senators Frockt, Fain, Pedersen, and Chase; by request of Attorney
More informationPATENT INFORMATION. Cameron IP
Cameron IP Intellectual Property Law Suite 1401-1166 Alberni Street Vancouver, BC Canada V6E 3Z3 Tel: (604) 688-6442 Fax: (604) 688-6445 Email: info@cameronip.com Website: www.cameronip.com What is a Patent?
More informationThe 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
More informationPay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions. An FTC Staff Study January 2010. Federal Trade Commission ftc.
Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions An FTC Staff Study January 2010 Federal Trade Commission ftc.gov Summary Brand-name pharmaceutical companies can delay generic competition
More informationTransatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth
Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth 1 About EFPIA Þ EFPIA is the voice of the European innovative pharmaceutical industry,
More informationPharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story
Pharma Lifecycle Management and Brand Defense Strategy Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy 20 July 2014 Terminology
More informationInvesting in Invention TM
To Promote the Progress of Useful Arts Investing in Invention TM Peter N. Detkin Founder, Vice Chairman, Intellectual Ventures 1 A THRIVING MARKETPLACE FOR IDEAS Current market undervalues invention and
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationDifferentiated IP Regimes for Environmental & Climate Technologies. Keith Maskus ICCG ICARUS International Workshop Venice, May 20, 2011
Differentiated IP Regimes for Environmental & Climate Technologies Keith Maskus ICCG ICARUS International Workshop Venice, May 20, 2011 Background Critical needs for new mitigation and adaptation technologies.
More informationPhilippines Philippines Philippinen. Report Q202. in the name of the Philippine Group by Rogelio NICANDRO
Philippines Philippines Philippinen Report Q202 in the name of the Philippine Group by Rogelio NICANDRO The impact of public health issues on exclusive patent rights Questions I) Analysis of current law
More informationAn Empirical Approach To Reverse Payment Settlements
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com An Empirical Approach To Reverse Payment Settlements
More informationOvercoming Restriction Requirements On Pharma Patents
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Overcoming Restriction Requirements On Pharma Patents
More informationInventions & Patents: Marketing a New Idea
Inventions & Patents: Marketing a New Idea About Intellectual Property Intellectual Property (IP) refers to the rights assigned to individuals who have created an original work. This can include inventions,
More informationGUIDELINES FOR THE CUSTOMIZATION OF THE PATENT GUIDE INVENTING THE FUTURE - AN INTRODUCTION TO PATENTS FOR SMALL AND MEDIUM-SIZED ENTERPRISES
GUIDELINES FOR THE CUSTOMIZATION OF THE PATENT GUIDE INVENTING THE FUTURE - AN INTRODUCTION TO PATENTS FOR SMALL AND MEDIUM-SIZED ENTERPRISES Overall objective The main objective of customizing the guide
More informationDrivers and Barriers to Australian Innovation
Drivers and Barriers to Australian Innovation Rail Innovation Australia Pty Ltd Case Study Mr Brian Bock Director RIA Prof Peter Robinson Director RIA Dr Anna Thomas General Manager RIA 9 August 2013 Australia
More informationMerger Market M&A Insights: Spotlight on IP Rights. Bliss White, Partner, Blake, Cassels & Graydon LLP
Merger Market M&A Insights: Spotlight on IP Rights Bliss White, Partner, Blake, Cassels & Graydon LLP Brand Migration - Due Diligence and Contract Issues Challenges re IP due diligence Consequences of
More informationProfiting from Non-Technological Innovation: The Value of Patenting. Novak druce centre insights No. 8
Profiting from Non-Technological Innovation: The Value of Patenting Business METHODS Novak druce centre insights No. 8 contents 01 Introduction: An Unexplored Area 02 Patenting Non-Technological Innovation
More informationItaly. Roundtable on: Role of Competition in the Pharmaceutical Sector and its Benefits for Consumers
Seventh United Nations Conference to review the UN Set on Competition Policy Geneva, 6-10 July 2015 Roundtable on: Role of Competition in the Pharmaceutical Sector and its Benefits for Consumers Statement
More informationConsultation on the future of European Insolvency Law
Consultation on the future of European Insolvency Law The Commission has put the revision of the Insolvency Regulation in its Work Programme for 2012. The revision is one of the measures in the field of
More informationPATENT BOX HOW TO MAXIMISE THE BENEFITS
PATENT BOX HOW TO MAXIMISE THE BENEFITS On 1 April 2013 the government introduced a low tax regime applicable to a company s profits, derived from the commercial exploitation of inventions protected by
More informationHow To Plan A Patent Portfolio
Patent Strategy for Emerging Companies Enterprise Works University of Illinois July 12, 2011 Chirag Shah CEO Mogambo Solutions alexandria chicago minneapolis champaign Outline Business and Patent Portfolio
More informationComité Economique des Produits de Santé
Comité Economique des Produits de Santé Summary of the activity report for 1999 CEPS 8 avenue de Ségur 75350 Paris SP 07 Activity Report for 1999 1 In accordance with Article D.162-2-5 of the Social Security
More informationNovozymes use of patents
Novozymes use of patents Preben Rasmussen, Ph. D. European Patent Attorney 2 Introduction Preben Rasmussen, Department Manager for EnzymeBusiness-patents DK Civilingeniør 1988, DTU Ph D 1991, DTU European
More informationInspections and Access to Evidence in
Inspections and Access to Evidence in Patent Litigation 10 th Annual Conference on Intellectual Property Law & Policy at Fordham IP Law Institute April, 12 th 2012, New York by Dr. Klaus Grabinski Judge
More informationA Guide To Conducting IP Due Diligence In M&A
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com A Guide To Conducting IP Due Diligence In M&A Law360,
More informationTransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet
TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating
More informationPatenting Software and Services. -stakeholder view-
Patenting Software and Services -stakeholder view- Dr. Harald Hagedorn SAP AG OECD Conference IPR, innovation and economic performance 28-29 August 23 Patent system Principles of the Patent System - provide
More informationINTRODUCTION TO TRADE MARKS INTRODUCTION TO TRADE MARKS
INTRODUCTION TO TRADE MARKS INTRODUCTION TO TRADE MARKS Trade Marks are the signs used by businesses to distinguish their goods and services from those of each other. It is important to choose trade marks
More informationProgram: Master s of Intellectual Property Law (Comprehensive) Syllabus
Program: Master s of Intellectual Property Law (Comprehensive) Syllabus Syllabus No. 2005 C A. GENERAL RULES AND CONDITIONS: 1. This plan Conforms to the valid regulations of programs of graduate studies.
More informationDraft Report of the Dispute Settlement Subcommittee, Intellectual Property Policy Committee, Industrial Structure Council
Draft Report of the Dispute Settlement Subcommittee, Intellectual Property Policy Committee, Industrial Structure Council October 2002 Table of Contents Chapter 1 Overview and Problems of Legal Systems
More informationSubmission Concerning Competition in Credit Card Payment Systems in Australia and the Formation of the Australian Payments Council
CSR LIMITED Locked Bag 1345 North Ryde BC NSW 1670 Australia www.csr.com.au ABN 90 000 001 276 26 August 2014 The Chairman Financial System Inquiry By on-line submission Dear Sir, Submission Concerning
More informationThe Patent Box. Background to the Patent Box regime
The Patent Box Background to the Patent Box regime The UK Government has been keen to improve the UK s competitiveness in the high-tech arena. Companies have been able to elect to enter the Patent Box
More informationHow to build a patent sales programme. Art Monk, TechInsights. Yearbook. Building IP value in the 21st century
How to build a patent sales programme Art Monk, TechInsights Yearbook 2015 Building IP value in the 21st century In a connected world, is your patent portfolio performing? Get results with TechInsights
More informationProposals to streamline IP processes and support small business. SUBMISSION by the OFFICE OF THE AUSTRALIAN SMALL BUSINESS COMMISSIONER
Proposals to streamline IP processes and support small business SUBMISSION by the OFFICE OF THE AUSTRALIAN SMALL BUSINESS COMMISSIONER April 2015 This is a submission by the Office of the Australian Small
More informationENFORCEMENT OF TRADEMARK RIGHTS ON THE INTERNET: NUTS AND BOLTS TOOLS TO HELP PROTECT AGAINST INFRINGEMENT. By Joan K. Archer, Ph.D., J.D.
ENFORCEMENT OF TRADEMARK RIGHTS ON THE INTERNET: NUTS AND BOLTS TOOLS TO HELP PROTECT AGAINST INFRINGEMENT I. Introduction. By Joan K. Archer, Ph.D., J.D. ABA June 2012 Regional Intellectual Property CLE
More informationCases COMP/AT.39740 Google Google s revised proposed commitments BEUC response to the questionnaire
Cases COMP/AT.39740 Google Google s revised proposed commitments BEUC response to the questionnaire Contact: Kostas Rossoglou/ Augusta Maciulevičiũtě digital@beuc.eu Ref.: X/2013/078-25/11/2013 BUREAU
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationBig Data An Opportunity or a Distraction? Signal or Noise?
Big Data An Opportunity or a Distraction? Signal or Noise? Maya R. Said, Sc.D. SVP & Global Head, Oncology Policy & Market Access, Novartis 3rd International Systems Biomedicine Symposium Luxembourg, 28
More informationIP and Finance - Accounting and Valuation of IP Assets and IP-based Financing - Topic 13 -
IP and Finance - Accounting and Valuation of IP Assets and IP-based Financing - Topic 13 - McLean Sibanda Partner: Sibanda & Zantwijk Attorneys, South Africa Training of the Trainers Program on Effective
More informationDrug Pricing System in Japan
Reference Chuikyo - 1 June 6, 2012 Drug Pricing System in Japan April 2012 (Underlined phrases in red in this text: New features and modifications to the current pricing system adopted by the 2012 system
More informationInternational Patent Litigation and Jurisdiction. Study of Hypothetical Question 1 Under the Hague Draft Convention and Japanese Laws
International Patent Litigation and Jurisdiction Study of Hypothetical Question 1 Under the Hague Draft Convention and Japanese Laws Yoshio Kumakura Attorney at Law Nakamura & Partners 1 The 1999 Draft
More informationLife sciences GROUP AN INTEGRATED APPROACH TO RISK MANAGEMENT
Life sciences PRACTICE GROUP AN INTEGRATED APPROACH TO RISK MANAGEMENT Global Markets International The business models for Life Sciences organisations are adapting to the new global environment. We understand
More informationJEFFREY AXELRAD S PRESENTATION FOR FDA TASK FORCE APRIL 14, 200 PUBLIC MEETING REGARDING IMPORTATION OF PRESCRIPTION DRUGS
FDA Docket # 2004N-0115 JEFFREY AXELRAD S PRESENTATION FOR FDA TASK FORCE APRIL 14, 200 PUBLIC MEETING REGARDING IMPORTATION OF PRESCRIPTION DRUGS I appreciate the opportunity you are providing to discuss
More informationREVISION OF EUROPEAN PATENT TRANSLATIONS TO INCLUDE CHEMICAL-PHARMACEUTICAL PRODUCT CLAIMS: A CHANGE OF DIRECTION?
MADRID Castellana, 216 28046 Madrid Tel.: (34) 91 582 91 00 BARCELONA Diagonal, 640 bis 08017 Barcelona Tel.: (34) 93 415 74 00 BILBAO Alameda Recalde, 36 48009 Bilbao Tel.: (34) 94 415 70 15 MALAGA Marqués
More informationINTELLECTUAL PROPERTY LAW FOR MOBILE TECHNOLOGY DEVELOPERS
INTELLECTUAL PROPERTY LAW FOR MOBILE TECHNOLOGY DEVELOPERS Chapter 2 2012 Hoffman Warnick LLC 1 Chapter II. A Basic IP Framework The purpose of this chapter is to convey a basic IP rights framework that
More informationIntellectual Property Rights Insurance. Slide 1
Intellectual Property Rights Insurance Slide 1 LBT Services Ltd Ernest Kay M.Sc. Barrister, ACIPA, F.Inst Directors Patent Insurance - General Overview Available in the UK & USA > 20 years Small Inventors
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationREFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN (POSTMENOPAUSAL VAGINAL ATROPHY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN Executive Summary Premarin (conjugated estrogen cream): Key Metrics in the Seven Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan
More informationPERSPECTIVE Drug Discovery Today Volume 17, Numbers 13/14 July 2012
drug development: an economically viable strategy for biopharma R&D feature Kiran N. Meekings 1, kiran.meekings@thomsonreuters.com, Cory S.M. Williams 2 and John E. Arrowsmith 1 drug incentives have stimulated
More informationHow companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
More information